Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDOcular Therapeutix, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$0.33 | -$0.26 | -$0.29 |
| Q2 2025 | 4 | -$0.38 | -$0.30 | -$0.36 |
| Q3 2025 | 4 | -$0.39 | -$0.32 | -$0.37 |
| Q4 2025 | 4 | -$0.35 | -$0.30 | -$0.32 |
| Q1 2026 | 3 | -$0.35 | -$0.33 | -$0.34 |
| Q2 2026 | 1 | -$0.53 | -$0.25 | -$0.35 |
| Q3 2026 | 1 | -$0.56 | -$0.27 | -$0.37 |
| Q4 2026 | 1 | -$0.57 | -$0.27 | -$0.37 |
| Q1 2027 | 1 | -$0.52 | -$0.25 | -$0.34 |
| Q2 2027 | 1 | -$0.52 | -$0.25 | -$0.34 |
| Q3 2027 | 1 | -$0.55 | -$0.26 | -$0.36 |
| Q4 2027 | 1 | -$0.49 | -$0.23 | -$0.32 |
Ocular Therapeutix, Inc. Earnings Date And Information
Ocular Therapeutix, Inc. last posted its earnings results on Tuesday, November 4th, 2025. The company reported $-0.37 earnings per share for the quarter, topping analysts' consensus estimates of $-0.39 by $0.02. The company had revenue of 14.54 M for the quarter and had revenue of 63.72 M for the year. Ocular Therapeutix, Inc. has generated $-1 earnings per share over the last year ($-1.22 diluted earnings per share) and currently has a price-to-earnings ratio of -9.36. Ocular Therapeutix, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 2nd, 2026 based on prior year's report dates.
Ocular Therapeutix, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/04/2025 | Q3 2025 | -$0.39 | -$0.38 | 0.01 | $14.64 M | $14.54 M |
| 08/05/2025 | Q2 2025 | -$0.35 | -$0.39 | -0.04 | $13.46 M | $13.46 M |
| 05/05/2025 | Q1 2025 | -$0.29 | -$0.38 | -0.09 | N/A | $10.70 M |
| 03/03/2025 | Q4 2024 | -$0.24 | -$0.29 | -0.05 | N/A | $17.08 M |
| 11/14/2024 | Q3 2024 | -$0.23 | -$0.22 | 0.01 | $17.13 M | $15.43 M |
| 08/07/2024 | Q2 2024 | -$0.22 | -$0.26 | -0.04 | $15.85 M | $16.44 M |
| 05/07/2024 | Q1 2024 | -$0.18 | -$0.49 | -0.31 | N/A | $14.77 M |
| 03/11/2024 | Q4 2023 | -$0.28 | -$0.21 | 0.07 | N/A | $14.80 M |
| 11/07/2023 | Q3 2023 | -$0.27 | -$0.27 | 0 | $15.23 M | $15.08 M |
| 08/07/2023 | Q2 2023 | -$0.29 | -$0.26 | 0.03 | $14.62 M | $15.19 M |
| 05/08/2023 | Q1 2023 | -$0.27 | -$0.39 | -0.12 | $14.09 M | $13.37 M |
| 03/06/2023 | Q4 2022 | -$0.25 | -$0.25 | 0 | $13.53 M | $14.08 M |
| 11/07/2022 | Q3 2022 | -$0.23 | -$0.31 | -0.08 | $14.27 M | $11.97 M |
| 08/08/2022 | Q2 2022 | -$0.23 | -$0.27 | -0.04 | $14.25 M | $12.27 M |
| 05/09/2022 | Q1 2022 | -$0.25 | -$0.24 | 0.01 | $13.96 M | $13.19 M |
| 02/28/2022 | Q4 2021 | -$0.23 | -$0.24 | -0.01 | $13.94 M | $12.31 M |
| 11/08/2021 | Q3 2021 | -$0.26 | -$0.26 | 0 | $12.45 M | $12.15 M |
| 08/09/2021 | Q2 2021 | -$0.20 | -$0.27 | -0.07 | $10.83 M | $11.72 M |
| 05/05/2021 | Q1 2021 | -$0.20 | -$0.27 | -0.07 | $7.64 M | $7.34 M |
| 03/11/2021 | Q4 2020 | -$0.18 | -$1.21 | -1.03 | $7.73 M | $7.35 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Ocular Therapeutix, Inc. Earnings: FAQ's
Ocular Therapeutix, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 2nd, 2026 based offlast year's report dates.
In the previous quarter, Ocular Therapeutix, Inc. (:OCUL) reported $-0.37 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.39 by $0.02.
The conference call for Ocular Therapeutix, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Ocular Therapeutix, Inc.'s latest earnings report can be read online.
Ocular Therapeutix, Inc. (:OCUL) has a recorded annual revenue of $63.72 M.
Ocular Therapeutix, Inc. (:OCUL) has a recorded net income of $-193,506,000.Ocular Therapeutix, Inc. has generated $-1.22 earnings per share over the last four quarters.
Ocular Therapeutix, Inc. (:OCUL) has a price-to-earnings ratio of -9.36 and price/earnings-to-growth ratio is 0.75.